Stem cells are seen by many as the great hope for medical research in the years to come. LSIPR spoke to Nicholas Seay, chief technology officer at Cellular Dynamics, about the importance of IP in this field.
In 2007, researchers discovered how to create human stem cells from adult human tissue, tackling one of the key controversies surrounding stem cell research by eliminating the need to use human embryos.
Any type of human cell can be created from these human donor-derived induced pluripotent stem (iPS) cells, which can aid in drug development and discovery by allowing researchers to study disease function and medical efficacy in vitro.
Wisconsin-based biotechnology firm Cellular Dynamics International uses iPS cells to produce different types of human cells to defined specifications on an industrial scale, which it offers to pharmaceutical companies in the business of drug discovery.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Cellular Dynamics, stem cells, induced pluripotent stem cells, drug discovery, IP strategy